Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

The "United States Oral Solid Dosage Contract Manufacturing Market, By Region, Competition, Forecast & Opportunities, ...

AbbVie will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Both parties will also expand research and development efforts. National Taiwan University Hospital (NTUH) and AbbVie ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

AbbVie的股价在过去12个月上涨了约11.8%。FactSet数据显示，超过60%的分析师对该股给予买入或增持评级，其平均目标价为179.44美元，意味着有13.7%的上涨潜力。 分析师对该股看法有分歧，仅有39%的人给予买入或增持评级。根据FactSet的数据，其平均目标价为14.83美元，意味着有11.9%的上涨潜力。

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

This was the stock's third consecutive day of losses.